Invention Grant
- Patent Title: Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
-
Application No.: US14421120Application Date: 2013-08-13
-
Publication No.: US09795665B2Publication Date: 2017-10-24
- Inventor: Eric Bergeron , Scott Dusan Pegan , Stuart T. Nichol , Michelle Kay Deaton
- Applicant: The United States of America as Represented by the Secretary of the Department of Health and Human Services , COLORADO SEMINARY, WHICH OWNS AND OPERATES THE UNIVERSITY OF DENVER
- Applicant Address: US DC Washington
- Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Current Assignee Address: US DC Washington
- Agency: Kilpatrick Townsend & Stockton LLP
- Agent Kevin Bastian
- International Application: PCT/US2013/054760 WO 20130813
- International Announcement: WO2014/028511 WO 20140220
- Main IPC: C12N7/00
- IPC: C12N7/00 ; A61K39/12 ; C12Q1/04 ; A61K39/00
Abstract:
The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
Public/Granted literature
- US20150306202A1 ATTENUATED LIVE VACCINE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS AND ERVE VIRUS Public/Granted day:2015-10-29
Information query
